Precision BioSciences Inc.

The momentum for this stock is not very good. Precision BioSciences Inc. has good value characteristics. Precision BioSciences Inc. is not very popular among insiders. Precision BioSciences Inc. is a mediocre stock to choose.

News

Precision BioSciences chief medical officer Alan List to retire

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Business Wire Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits...\n more…

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock

Zacks Investment Research Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks...\n more…

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade

Zacks Investment Research Precision BioSciences (DTIL) closed the last trading session at $9.71, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by...\n more…